BACKGROUND AND OBJECTIVES: Newborn Hearing Screening (NHS) program aims to identify babies at risk of hearing loss and provide appropriate rehabilitation within the crucial period for language development. The risk of hearing loss in increased in babies discharged from neonatal intensive care unit (NICU) compared to wellbaby nursery. Transient evoked otoacoustic emission (TEOAE) or automated auditory brainstem response tests are utilized. The purpose of this study is to assess the outcome of NHS using TEOAE as initial evaluation method in NICU graduates. SUBJECTS AND METHODS: TEOAE was performed as initial screening method for NHS in NICU neonates born between February 2010 and November 2011. Babies referred from TEOAE were reevaluated with repeated TEOAE or auditory brainstem response. Referral rates were estimated and quality indicators for screening (Joint Committee on Infant Hearing position statement, 2007) were evaluated. RESULTS: Among 149 neonates graduated from NICU, 50 (33.6%) babies failed initial TEOAE ('refer'). A second stage TEOAE testing was performed in 41 (82.0%) of these babies: 35 (85.4%) passed and 6 (14.6%) were referred for diagnostic testing. From 2-stage TEOAE screening program, 6 neonates were referred for diagnostic audiological evaluation: sensorineural hearing loss was identified in 2 babies and 3 babies were lost to follow up. Quality indicators for screening were as follows: 1) 94.0% of all newborn infants admitted to NICU completed screening by 1 month of age, and 2) 4.0% of all newborn infants who fail initial screening and fail any subsequent rescreening before comprehensive audiological evaluation. CONCLUSIONS: Timely and adequate screening of hearing loss is prerequisite for accurate diagnosis and appropriate rehabilitation in infants especially from NICU. Further refinement of the current NHS with additional reliable screening technology is required for more stable and successful screening program.
Diagnostic Tests, Routine ; Evoked Potentials, Auditory, Brain Stem ; Hearing ; Hearing Loss ; Hearing Loss, Sensorineural ; Humans ; Infant ; Infant, Newborn ; Intensive Care, Neonatal ; Language Development ; Lost to Follow-Up ; Mass Screening ; Nurseries ; Quality Indicators, Health Care ; Referral and Consultation

BACKGROUND AND OBJECTIVES: Newborn Hearing Screening (NHS) program aims to identify babies at risk of hearing loss and provide appropriate rehabilitation within the crucial period for language development. The risk of hearing loss in increased in babies discharged from neonatal intensive care unit (NICU) compared to wellbaby nursery. Transient evoked otoacoustic emission (TEOAE) or automated auditory brainstem response tests are utilized. The purpose of this study is to assess the outcome of NHS using TEOAE as initial evaluation method in NICU graduates. SUBJECTS AND METHODS: TEOAE was performed as initial screening method for NHS in NICU neonates born between February 2010 and November 2011. Babies referred from TEOAE were reevaluated with repeated TEOAE or auditory brainstem response. Referral rates were estimated and quality indicators for screening (Joint Committee on Infant Hearing position statement, 2007) were evaluated. RESULTS: Among 149 neonates graduated from NICU, 50 (33.6%) babies failed initial TEOAE ('refer'). A second stage TEOAE testing was performed in 41 (82.0%) of these babies: 35 (85.4%) passed and 6 (14.6%) were referred for diagnostic testing. From 2-stage TEOAE screening program, 6 neonates were referred for diagnostic audiological evaluation: sensorineural hearing loss was identified in 2 babies and 3 babies were lost to follow up. Quality indicators for screening were as follows: 1) 94.0% of all newborn infants admitted to NICU completed screening by 1 month of age, and 2) 4.0% of all newborn infants who fail initial screening and fail any subsequent rescreening before comprehensive audiological evaluation. CONCLUSIONS: Timely and adequate screening of hearing loss is prerequisite for accurate diagnosis and appropriate rehabilitation in infants especially from NICU. Further refinement of the current NHS with additional reliable screening technology is required for more stable and successful screening program.
Diagnostic Tests, Routine ; Evoked Potentials, Auditory, Brain Stem ; Hearing ; Hearing Loss ; Hearing Loss, Sensorineural ; Humans ; Infant ; Infant, Newborn ; Intensive Care, Neonatal ; Language Development ; Lost to Follow-Up ; Mass Screening ; Nurseries ; Quality Indicators, Health Care ; Referral and Consultation

Objectives: Liraglutide is a glucagon-like-peptide-1 receptor agonist which has been used as an anti-obesity drug. It was reported that patients might develop or worsen suicidal ideas and/or depression during liraglutide treatment, especially when it comes to patients with a psychiatric disorder. The purpose of this study was to evaluate the effectiveness and safety of liraglutide, especially in terms of the psychiatric adverse effects. Methods: A retrospective chart review study was conducted on psychiatric patients prescribed liraglutide for more than one month from September 2018 to September 2020. Based on their medical records, we investigated the change in the weight and body mass index (BMI) of patients from the baseline to 6 months of receiving liraglutide treatment. Information on the adverse effects was also obtained, including psychiatric adverse effects such as insomnia, anxiety, depression, and suicidal ideation. A mixed linear model was used for assessing the time effect on change in weight and BMI. Results: A total of 24 patients were included in the current study, and the most common psychiatric diagnosis included major depressive disorder (n=13, 54.2%). There was a significant change in weight (F=6.127, p=0.001) and BMI (F=6.749, p<0.001) during the liraglutide treatment. Worsening of depression and anxiety occurred in one patient but improved after the adjustment of psychiatric medications. Conclusion The current study found that liraglutide treatment in patients with a psychiatric disorder can be a safe and effective intervention for weight reduction.